TGTX241206P18000
- 0.15
- 0.000.00%
TG Therapeutics Newsroom
Unusual Options Activity: XP, CRS and Others Attract Market Bets, XP V/OI Ratio Reaches 384.6
EST Dec 10th Afternoon Delivery - In the last two hours of trading, 8 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Is TG Therapeutics (NASDAQ:TGTX) Using Too Much Debt?
TG Therapeutics to Participate in the Evercore HealthCONx Conference
TG Therapeutics Is Maintained at Overweight by JP Morgan
TG Therapeutics Analyst Ratings
J.P. Morgan Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $43
A Closer Look at TG Therapeutics's Options Market Dynamics
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500
10 Health Care Stocks Whale Activity In Today's Session
Don't Ignore The Insider Selling In TG Therapeutics
TG Therapeutics | 10-Q: Q3 2024 Earnings Report
Subdued Growth No Barrier To TG Therapeutics, Inc. (NASDAQ:TGTX) With Shares Advancing 27%
TG Therapeutics Price Target Raised to $55.00/Share From $49.00 by HC Wainwright & Co.
TG Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Goldman Sachs Maintains Neutral on TG Therapeutics, Raises Price Target to $22
A Quick Look at Today's Ratings for TG Therapeutics(TGTX.US), With a Forecast Between $38 to $55
TG Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
TG Therapeutics Boosts Revenue Outlook Amidst Growth
TG Therapeutics: Promising Growth Trajectory and Blockbuster Potential Justify Buy Rating
TG Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Transcript Summary